Very low enalapril and enalaprilat exposure <i>via</i> human milk: a case report from the ConcePTION project.

ABSTRACT:

Introduction

Ongoing maternal and clinical hesitancy in breastfeeding-related shared decision-making is driven by limited safety data on maternal pharmacotherapy. Theoretical exposure to maternal enalapril and its active metabolite enalaprilat in breastfed infants has previously been reported in two studies of eight mother-infant pairs. However, actual infant plasma concentrations remain uncharacterized.

Methods

A 30-year-old white woman started enalapril (5 mg, 1x/day) for IgA nephropathy at 11 weeks postpartum while exclusively breastfeeding. On day 101 postpartum, 25 days after therapy start, she collected six steady-state milk samples over 24 h, along with two maternal and one infant blood sample, used to calculate milk-to-plasma (M/P) ratio and estimated infant exposure

SUBMITTER: Jacobs E 

PROVIDER: S-EPMC12864425 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature